The impact of informed consent on patient interest in prostate-specific antigen screening

Archives of Internal Medicine

Volumn 156, Issue 12, 1996, Pages 1333-1336

  Wolf, Andrew M D ^a   Nasser, Jonathan F ^b   Wolf, Anne M ^c,d   Schorling, John B ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FAMILY HISTORY; HUMAN; INFORMED CONSENT; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PUBLIC HEALTH INSURANCE; RANDOMIZED CONTROLLED TRIAL;

CANCER; CLINICAL APPROACH/SOURCE; CONTROL GROUPS; DISADVANTAGED; EMPIRICAL APPROACH; HEALTH CARE AND PUBLIC HEALTH; INFORMATION DISSEMINATION; MALES; PROFESSIONAL PATIENT RELATIONSHIP; RISKS AND BENEFITS; UNCERTAINTY;

AGED; CONTROL GROUPS; DECISION MAKING; DISCLOSURE; HUMANS; INFORMATION DISSEMINATION; INFORMED CONSENT; MALE; MASS SCREENING; MIDDLE AGED; PATIENT EDUCATION; PATIENT PARTICIPATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; UNCERTAINTY; VULNERABLE POPULATIONS;

EID: 0029938269     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.12.1333     Document Type: Article

References (16)

1. Wingo PA, Tong T, Belden S. Cancer statistics: 1995. CA Cancer J Clin. 1995; 45:8-30.
2. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273: 289-294.
3. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948-954.
4. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993; 119:914-923.
5. Walsh PC. Using prostate-specific antigen to diagnose prostate cancer: sailing in uncharted waters. Ann Intern Med. 1993;119:948-949.
6. Chodak GW. Screening for prostate cancer in 1993: is it appropriate or not? Semin Urol. 1993;11:47-49.
7. Reynolds T. Prostate cancer experts debate screening, treatment at workshop. J Natl Cancer Inst. 1993;85:1104-1106.
8. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer: a decision analytic view. JAMA. 1994;272:773-780.
9. Brawer MK. How to use prostate-specific antigen in the early detection or screening for prostatic carcinoma. CA Cancer J Clin. 1995;45:148-164.
10. Gesenway D. Communication is vital in treating prostate diseases. ACP Observer. 1995;15:11.
11. Handley MR, Stuart ME. The use of prostate-specific antigen for prostate cancer screening: a managed care perspective. J Urol. 1994;152:1689-1692.
12. Dorr VJ, Williamson SK, Stephens RL. An evaluation of prostate-specific antigen as a screening test for prostate cancer. Arch Intern Med. 1993;153:2529-2537.
13. Ruckle HC, Klee GG, Oesterling JE. Prostate-specific antigen: critical issues for the practicing physician. Mayo Clin Proc. 1994;69:59-68.
14. Hahn DL, Roberts RG. PSA screening for asymptomatic prostate cancer: truth in advertising. J Fam Pract. 1993;37:432-436.
15. Gohagan JK, Prorok PC, Kramer BS, Cornett JE. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. J Urol. 1994;152:1905-1909.
16. Wilt TJ, Brawer MK. The prostate cancer intervention versus observation trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer J Urol. 1994; 152:1910-1914.